Table 1.
Cell line | pRB | p107 | p130 |
---|---|---|---|
GLC2 | − | + | − |
GLC3 | + | + | + |
GLC14 | − | + | + |
GLC16 | − | + | + |
GLC19 | − | + | + |
GLC26 | − | + | + |
GLC28 | − | + | + |
DMS53 | + | + | + |
DMS79 | − | + | + |
DMS92 | + | + | + |
DMS114 | + | + | + |
DMS153 | − | + | + |
DMS273 | + | + | + |
DMS406 | − | + | + |
DMS456 | + | + | + |
CPH54A | + | + | + |
CPH54B | + | + | + |
Expression of p107 and p130 was evaluated by Western blotting and binding to GSTE1A. The data for pRB expression have previously been published by Rygård et al. (20), except for GLC2, GLC26, GLC28, and DMS406, which were tested by Western blotting and binding to GSTE1A. A + indicates that the wild-type protein is expressed; a − indicates no expression or that a mutated protein is expressed. The GLC14, GLC16, and GLC19 cell lines are derived from the same patient. CPH54A and CPH54B are derived from a different single patient.